1
|
Salvarredi L, Oglio RA, Rodriguez C, Navarro D, Perona M, Dagrosa MA, Juvenal GJ, Thomasz L. 2-iodohexadecanal induces autophagy during goiter involution. Prostaglandins Other Lipid Mediat 2024; 172:106819. [PMID: 38346574 DOI: 10.1016/j.prostaglandins.2024.106819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 11/03/2023] [Accepted: 02/09/2024] [Indexed: 02/24/2024]
Abstract
BACKGROUND Iodine plays an important role in thyroid physiology and biochemistry. The thyroid is capable of producing different iodolipids such as 2-iodohexadecanal (2-IHDA). Data from different laboratories have shown that 2-IHDA inhibits several thyroid parameters and it has been postulated as intermediary on the action of iodide function. OBJECTIVE To explore different mechanisms involved during the involution of the hyperplastic thyroid gland of Wistar rats towards normality induced by 2-IHDA. METHODS Goiter was induced by the administration of MMI for 10 days, then the treatment was discontinued and Wistar rats were injected with 2-IHDA or KI. RESULTS During involution, 2-IHDA treatment reduced PCNA expression compared to spontaneous involution. KI treatment caused an increase of Caspase-3 activity and TUNEL-positive cells. In contrast, 2-IHDA failed to alter this value but induced an increase of LC3B expression. KI but not 2-IHDA led to an increase in peroxides levels, catalase and glutathione peroxidase activity. CONCLUSIONS We demonstrated that 2-IHDA, in contrast to iodide, did not lead to an increase in oxidative stress or apoptosis induction, indicating that the involution triggered by 2-IHDA in Wistar rats, is primarily due to the inhibition of cell proliferation and the induction of autophagy.
Collapse
Affiliation(s)
- Leonardo Salvarredi
- Nuclear Medicine School Foundation (FUESMEN), National Commission of Atomic Energy (CNEA), Mendoza, Argentina; Instituto Balseiro, National Comission of Atomic Energy & National University of Cuyo, Mendoza, Argentina
| | - Romina A Oglio
- Department of Radiobiology (CAC), National Commission of Atomic Energy (CNEA), Buenos Aires, Argentina
| | - Carla Rodriguez
- Department of Radiobiology (CAC), National Commission of Atomic Energy (CNEA), Buenos Aires, Argentina
| | | | - Marina Perona
- Department of Radiobiology (CAC), National Commission of Atomic Energy (CNEA), Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), CABA, Argentina
| | - María A Dagrosa
- Department of Radiobiology (CAC), National Commission of Atomic Energy (CNEA), Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), CABA, Argentina
| | - Guillermo J Juvenal
- Department of Radiobiology (CAC), National Commission of Atomic Energy (CNEA), Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), CABA, Argentina
| | - Lisa Thomasz
- Department of Radiobiology (CAC), National Commission of Atomic Energy (CNEA), Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), CABA, Argentina.
| |
Collapse
|
2
|
Oglio R, Rodriguez C, Salvarredi L, Rossich L, Perona M, Dagrosa A, Juvenal G, Thomasz L. Selenium bioavailability modulates the sensitivity of thyroid cells to iodide excess. Chem Biol Interact 2024; 387:110810. [PMID: 38013145 DOI: 10.1016/j.cbi.2023.110810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 10/25/2023] [Accepted: 11/15/2023] [Indexed: 11/29/2023]
Abstract
INTRODUCTION Iodide is an essential micronutrient for the synthesis of thyroid hormones and its imbalance is involved in the origin of different thyroid pathological processes. Selenium (Se) is another essential trace element that contributes to thyroid preservation through the control of the redox homeostasis. Different studies have demonstrated that sodium-iodide-symporter (NIS) is downregulated in the presence of iodide excess and Se supplementation reverses this effect. We also demonstrated that NOX4-derived ROS are involved in NIS repression induced by iodide excess. The aim of this study was to investigate how Se bioavailability is decisive in the sensitivity to iodide excess on a differentiated rat thyroid cell line (FRTL-5). RESULTS We demonstrated that siRNA-mediated silencing of Nox4 suppressed AKT phosphorylation induced by iodide excess. Iodide increases TGF-β1 mRNA expression, AKT phosphorylation, ROS levels and decreases GPX1 and TXRND1 mRNAs expression while Se reversed these effects. Furthermore, iodide induced Nrf2 transcriptional activity only in Se-supplemented cultures, suggesting that Se positively influences Nrf2 activation and selenoenzyme response in FRTL-5. Se, also inhibited NF-κB phosphorylation induced by iodide excess. In addition, we found that iodide excess decreased total phosphatase activity and PTP1B and PTEN mRNA expression. Se supply restored only PTEN mRNA expression. Finally, we studied the 2-α-iodohexadecanal (2-IHD) effects since it has been proposed as intermediary of iodide action on thyroid autoregulation. 2-IHD stimulated PI3K/AKT activity and reduced NIS expression by a ROS-independent mechanism. Also, we found that 2-IHD increased TGF-β1 mRNA and TGF-β inhibitor (SB431542) reverses the 2-IHD inhibitory effect on NIS mRNA expression, suggesting that TGF-β1 signaling pathway could be involved. Although Se reduced 2-IHD-induced TGFB1 levels, it could not reverse its inhibitory effect on NIS expression. CONCLUSION Our study suggests that Se bioavailability may improve the expression of antioxidant genes through the activation of Nrf2, interfere in PI3K/AKT signaling and NIS expression by redox modulation.
Collapse
Affiliation(s)
- Romina Oglio
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina
| | - Carla Rodriguez
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina
| | - Leonardo Salvarredi
- FUESMEN, Mendoza, Argentina; Balseiro Institute, National University of Cuyo, Mendoza, Argentina
| | - Luciano Rossich
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina
| | - Marina Perona
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina; CONICET, Buenos Aires, Argentina
| | - Alejandra Dagrosa
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina; CONICET, Buenos Aires, Argentina
| | - Guillermo Juvenal
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina; CONICET, Buenos Aires, Argentina
| | - Lisa Thomasz
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires, Argentina; CONICET, Buenos Aires, Argentina.
| |
Collapse
|
3
|
Perona M, Ibañez IL, Thomasz L, Villaverde MS, Oglio R, Rosemblit C, Grissi C, Campos-Haedo M, Dagrosa MA, Cremaschi G, Durán HA, Juvenal GJ. Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity. J Endocrinol Invest 2023; 46:2353-2365. [PMID: 37052871 DOI: 10.1007/s40618-023-02092-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 04/06/2023] [Indexed: 04/14/2023]
Abstract
BACKGROUND Anaplastic thyroid cancer (ATC) represents a rare lethal human malignancy with poor prognosis. Multimodality treatment, including radiotherapy, is recommended to improve local control and survival. Valproic acid (VA) is a clinically available histone deacetylase inhibitor with a well-documented side effect profile. In this study, we aim to investigate the combined effect of VA with photon irradiation in vitro. METHODS Anaplastic thyroid cancer cells (8505c) were used to investigate the radiosensitizing effect of VA. RESULTS VA sensitized cells to photon irradiation. VA increased radiation-induced apoptosis and radiation-induced DNA damage measured by γH2AX foci induction. Furthermore, VA prolonged γH2AX foci disappearance over time in irradiated cells and decreased the radiation-induced levels of mRNA of key DNA damage repair proteins of the homologous recombination (HR) and the nonhomologous end joining (NHEJ) pathways. CONCLUSIONS VA at a clinically safe dose enhance the radiosensitivity of 8505c cells through an increase in radiation-induced apoptosis and a disruption in the molecular mechanism of HR and NHEJ DNA damage repair pathways.
Collapse
Affiliation(s)
- M Perona
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina.
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina.
| | - I L Ibañez
- Institute of Nanosciences and Nanotechnology (INN), CNEA-CONICET, Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
| | - L Thomasz
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina
| | - M S Villaverde
- Gene Transfer Unit (UTG), Research Area, 'Ángel H. Roffo' Institute of Oncology of the University of Buenos Aires, Av. San Martín 5481, C1417DTB, CABA, Buenos Aires, Argentina
| | - R Oglio
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
| | - C Rosemblit
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina
- Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Av. Alicia Moreau de Justo 1600, C1107AFF, Buenos Aires, Argentina
| | - C Grissi
- Institute of Nanosciences and Nanotechnology (INN), CNEA-CONICET, Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
| | - M Campos-Haedo
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina
- Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Av. Alicia Moreau de Justo 1600, C1107AFF, Buenos Aires, Argentina
| | - M A Dagrosa
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina
| | - G Cremaschi
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina
- Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Av. Alicia Moreau de Justo 1600, C1107AFF, Buenos Aires, Argentina
| | - H A Durán
- Institute of Nanosciences and Nanotechnology (INN), CNEA-CONICET, Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
- School of Science and Technology, University of San Martín (UNSAM), 25 de Mayo y Francia, B1650KNA, Buenos Aires, Argentina
| | - G J Juvenal
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. General Paz 1499, B1650KNA, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, C1425FQD, CABA, Buenos Aires, Argentina
| |
Collapse
|
4
|
Grissi C, Taverna Porro M, Perona M, Atia M, Negrin L, Moreno MS, Sacanell J, Olivera MS, Del Grosso M, Durán H, Ibañez IL. Superparamagnetic iron oxide nanoparticles induce persistent large foci of DNA damage in human melanoma cells post-irradiation. Radiat Environ Biophys 2023:10.1007/s00411-023-01037-0. [PMID: 37452828 DOI: 10.1007/s00411-023-01037-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 06/25/2023] [Indexed: 07/18/2023]
Abstract
The synergy of superparamagnetic iron oxide nanoparticles (SPIONs) and ionizing radiation (IR), attributed to reactive oxygen species (ROS) and DNA double-strand breaks (DSBs) increase, was widely investigated in different cancers, but scarcely in melanoma. Herein, SPIONs were evaluated as radiosensitizers in A-375 human melanoma cells. Moreover, the effect of the combined treatment of SPIONs and gamma irradiation (SPIONs-IR) was assessed at the DNA level, where DSBs induction and their repair capacity were studied. SPIONs were synthesized, stabilized by poly(ethylene glycol) methyl ether and physicochemically characterized by high resolution-transmission electron microscopy (HR-TEM), X-ray diffraction and magnetometry and dynamic light scattering. The obtained nanoparticles showing superparamagnetic behavior and low dispersion in shape and sizes were tested in A-375 cells. The intracellular internalization of SPIONs was verified by HR-TEM and quantified by inductively coupled plasma atomic emission spectroscopy. Cells treated with SPIONs exhibited high ROS levels without associated cytotoxicity. Next, a significant radiosensitization in SPIONs-IR vs. control (IR) cells was demonstrated at 1 Gy of gamma radiation. Furthermore, a decreased DSBs repair capacity in SPIONs-IR vs. IR-treated cells was evidenced by the size increase of persistent phosphorylated H2AX foci at 24 h post-irradiation. In conclusion, these nanoparticles show the potential to radiosensitize melanoma cells by the induction of unrepairable DNA damage.
Collapse
Affiliation(s)
- Cecilia Grissi
- Subgerencia de Tecnología y Aplicaciones de Aceleradores, Gerencia de Investigación y Aplicaciones, Comisión Nacional de Energía Atómica (CNEA), Instituto de Nanociencia y Nanotecnología (INN), CNEA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Constituyentes, Av. General Paz, 1499 (B1650KNA), San Martín, Buenos Aires, Argentina
| | - Marisa Taverna Porro
- Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Universidad de Buenos Aires, Junín 954 (C1113AAD), Ciudad Autónoma de Buenos Aires, Argentina
- Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Campus Miguelete (B1650KNA), San Martín, Provincia de Buenos Aires, Argentina
| | - Marina Perona
- División Bioquímica Nuclear, Departamento de Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. General Paz 1499 (B1650KNA), San Martín, Buenos Aires, Argentina
| | - Mariel Atia
- Subgerencia de Tecnología y Aplicaciones de Aceleradores, Gerencia de Investigación y Aplicaciones, Comisión Nacional de Energía Atómica (CNEA), Instituto de Nanociencia y Nanotecnología (INN), CNEA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Constituyentes, Av. General Paz, 1499 (B1650KNA), San Martín, Buenos Aires, Argentina
| | - Lara Negrin
- Laboratorio de Radiobiología y Biodosimetría, Centro Atómico Bariloche, Comisión Nacional de Energía Atómica (CNEA), Centro de Medicina Nuclear y Radioterapia - Instituto de Tecnologías Nucleares Para La Salud (INTECNUS), Av. Bustillo Km. 9,5 (R8402AGP), S.C. de Bariloche, Río Negro, Argentina
| | - M Sergio Moreno
- Instituto de Nanociencia y Nanotecnología (INN), Comisión Nacional de Energía Atómica (CNEA) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Bariloche, Centro Atómico Bariloche, Av. Bustillo Km. 9,5 (R8402AGP), S.C. de Bariloche, Río Negro, Argentina
| | - Joaquín Sacanell
- Departamento de Física de la Materia Condensada, Comisión Nacional de Energía Atómica (CNEA), Instituto de Nanociencia y Nanotecnología (INN), CNEA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Constituyentes, Av. General Paz 1499 (B1650KNA), San Martín, Buenos Aires, Argentina
| | - María Silvina Olivera
- Departamento Coordinación BNCT, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes, Av. General Paz 1499 (B1650KNA), San Martín, Buenos Aires, Argentina
| | - Mariela Del Grosso
- Subgerencia de Tecnología y Aplicaciones de Aceleradores, Gerencia de Investigación y Aplicaciones, Comisión Nacional de Energía Atómica (CNEA), Instituto de Nanociencia y Nanotecnología (INN), CNEA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Constituyentes, Av. General Paz, 1499 (B1650KNA), San Martín, Buenos Aires, Argentina
| | - Hebe Durán
- Subgerencia de Tecnología y Aplicaciones de Aceleradores, Gerencia de Investigación y Aplicaciones, Comisión Nacional de Energía Atómica (CNEA), Instituto de Nanociencia y Nanotecnología (INN), CNEA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Constituyentes, Av. General Paz, 1499 (B1650KNA), San Martín, Buenos Aires, Argentina.
- Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Campus Miguelete (B1650KNA), San Martín, Provincia de Buenos Aires, Argentina.
| | - Irene L Ibañez
- Subgerencia de Tecnología y Aplicaciones de Aceleradores, Gerencia de Investigación y Aplicaciones, Comisión Nacional de Energía Atómica (CNEA), Instituto de Nanociencia y Nanotecnología (INN), CNEA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nodo Constituyentes, Av. General Paz, 1499 (B1650KNA), San Martín, Buenos Aires, Argentina.
| |
Collapse
|
5
|
Haedo MNC, Flaque MCD, Sterle HA, Albuja JAD, Cayrol MF, Debernardi MM, Perona M, Juvenal GJ, Cremaschi GA, Rosemblit C. Abstract 3073: Action of thyroid hormones in sorafenib treatment of thyroid cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-3073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Thyroid carcinoma (TC) is the most common endocrine neoplasia. Its incidence has increased in the last 40 years worldwide. Sorafenib (Sor), a tyrosine kinase inhibitor (TKI), was approved for the treatment of TC, being hypothyroidism the most frequent consequence of Sor-induced endocrine dysfunction. We have described that thyroid hormones (TH) increase cell proliferation in TC cell lines. Thus, hormone replacement therapy to treat Sor-induced hypothyroidism could negatively affect its antitumor action. We have also shown that the selective inhibition of the TH membrane receptor, integrin αVβ3, diminishes proliferation.
Objective: To study integrin αVβ3 inhibition to enhance Sor antineoplastic activity in TC and the molecular mechanisms involved.
Experimental Procedures: 8505C human anaplastic TC cell viability was evaluated by MTS
assay. Sor was the TKI used, and Cilengitide (Cile) was used to inhibit integrin αVβ3. Protein modulation was measured by Western blot. Apoptosis induction was determined by APC-Annexin V Propidium iodide staining, followed by flow cytometry. In silico analysis on several databases were
performed using CBioPortal (https://cbioportal.org/; TCGA, Cell 2014, n=504) and R2 (http://r2.amc.nl; GSE126729, n=28).
Results: We first performed a bioinformatic analysis by cBioPortal on the PanCancer Atlas data and found that thyroid tumors are those with the highest integrin αVβ3 subunits expression. We then studied the role of integrin αVβ3 in Sor inhibition of TH-induced proliferation in TC cells. Treatment of 8505C cells with integrin αVβ3 antagonist Cile inhibits TH-induced proliferation (p<0.0001), confirming the participation of the integrin. As expected, Sor treatment decreases proliferation (p<0.05) while Cile addition did not change the inhibition level. Also, we found that Sor and Cile treatment diminished PCNA and Cyclin D1 expression levels. Cells were preincubated with Sor and Cile and then treated or not with TH for 48h to analyze apoptosis. Sor treatment increases the number of apoptotic cells relative to untreated control (p<0.0001) and the presence of TH reduces the rate of apoptosis (p<0.01). We then studied Sor target genes expression by R2 on an anaplastic TC patients’ database. FGFR is highly expressed among Sor targets, and it is correlated with integrin αVβ3 expression. Thus, FGFR expression modulation was studied by Western blot on cells treated as previously described. Finally, we found that TH treatment increased FGFR expression, Sor diminishes expression and in presence of TH, FGFR expression was rescued. Interestingly, Cile addition resensitized cells to Sor in presence of TH.
Conclusion: Our results establish that the effective dual Sor and Cile treatment can significantly drive tumor proliferation inhibition and apoptosis, and it could provide alternatives to the treatments currently used for this disease.
Citation Format: Mateo N. Campos Haedo, Maria C. Diaz Flaque, Helena A. Sterle, Johanna A. Diaz Albuja, Maria F. Cayrol, Maria M. Debernardi, Marina Perona, Guillermo J. Juvenal, Graciela A. Cremaschi, Cinthia Rosemblit. Action of thyroid hormones in sorafenib treatment of thyroid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3073.
Collapse
Affiliation(s)
| | - Maria C. Diaz Flaque
- 1Inst de Investigaciones Biomédicas UCA-CONICET (BIOMED), Buenos Aires, Argentina
| | - Helena A. Sterle
- 1Inst de Investigaciones Biomédicas UCA-CONICET (BIOMED), Buenos Aires, Argentina
| | | | - Maria F. Cayrol
- 1Inst de Investigaciones Biomédicas UCA-CONICET (BIOMED), Buenos Aires, Argentina
| | - Maria M. Debernardi
- 1Inst de Investigaciones Biomédicas UCA-CONICET (BIOMED), Buenos Aires, Argentina
| | - Marina Perona
- 2Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | | | | | - Cinthia Rosemblit
- 1Inst de Investigaciones Biomédicas UCA-CONICET (BIOMED), Buenos Aires, Argentina
| |
Collapse
|
6
|
Couto M, Alamón C, Nievas S, Perona M, Dagrosa MA, Teixidor F, Cabral P, Viñas C, Cerecetto H. Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer. Chemistry 2020; 26:14335-14340. [PMID: 32738078 DOI: 10.1002/chem.202002963] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 07/26/2020] [Indexed: 12/17/2022]
Abstract
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells and found to be 4 times more cytotoxic than sunitinib and 1.7 times more effective than 10 B-boronophenylalanine fructose complex when the cells were irradiated with neutrons.
Collapse
Affiliation(s)
- Marcos Couto
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Catalina Alamón
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay
| | - Susana Nievas
- Department of Boron Neutron Capture Therapy, National Atomic Energy Commission (CNEA), Buenos Aires, Argentina
| | - Marina Perona
- Department of Radiobiology, CNEA, Buenos Aires, Argentina
| | | | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares (CIN), Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Hugo Cerecetto
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Área de Radiofarmacia, Centro de Investigaciones Nucleares (CIN), Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| |
Collapse
|
7
|
Perona M, Majdalani ME, Rodríguez C, Nievas S, Carpano M, Rossini A, Longhino JM, Cabrini R, Pisarev MA, Juvenal GJ, Dagrosa MA. Experimental studies of boron neutron capture therapy (BNCT) using histone deacetylase inhibitor (HDACI) sodium butyrate, as a complementary drug for the treatment of poorly differentiated thyroid cancer (PDTC). Appl Radiat Isot 2020; 164:109297. [PMID: 32768887 DOI: 10.1016/j.apradiso.2020.109297] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 02/19/2020] [Accepted: 06/14/2020] [Indexed: 11/30/2022]
Abstract
PURPOSE The present study analyzed different protocols of administration of boronophenylalanine (BPA) and sodium butyrate (NaB) to increase the BNCT efficacy for poorly differentiated thyroid cancer (PDTC). MATERIALS AND METHODS Nude mice implanted with human PDTC cells (WRO) were distributed into four protocols: 1) BPA; 2) BPA + ip NaB; 3) BPA + oral NaB; 4) Control. Biodistribution and histologic studies were performed. LAT (BPA transporter) isoforms gene expression was assessed by RT-PCR. RESULTS Tumor growth delay was observed in animals of the Protocol #3 (p < 0.05). NaB (Protocol #2) increased tumor boron uptake 2-h post BPA injection (p < 0.05). On the other hand, NaB upregulated the expression of all the isoforms of the LAT transporter in vitro. Histologic studies showed a significant decrease of mitotic activity and an increase of vacuoles in tumors of Protocol #3. Neutrons alone or combined with NaB caused some tumor growth delay (p < 0.05), while in the BNCT and BNCT + NaB groups, there was a halt in tumor growth in 70 and 80% of the animals, respectively. CONCLUSIONS Intraperitoneally administration of NaB increased boron uptake while oral administration for a longer period of time induced tumor growth delay previous to BPA administration. The use of NaB via ip would optimize the irradiation results.
Collapse
Affiliation(s)
- M Perona
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290 (1425) CABA, Argentina
| | - M E Majdalani
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - C Rodríguez
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - S Nievas
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - M Carpano
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - A Rossini
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - J M Longhino
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - R Cabrini
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - M A Pisarev
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - G J Juvenal
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290 (1425) CABA, Argentina
| | - M A Dagrosa
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290 (1425) CABA, Argentina. http://
| |
Collapse
|
8
|
Guelfi S, Botia JA, Thom M, Ramasamy A, Perona M, Stanyer L, Martinian L, Trabzuni D, Smith C, Walker R, Ryten M, Reimers M, Weale ME, Hardy J, Matarin M. Transcriptomic and genetic analyses reveal potential causal drivers for intractable partial epilepsy. Brain 2019; 142:1616-1630. [DOI: 10.1093/brain/awz074] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 12/10/2018] [Accepted: 01/31/2019] [Indexed: 01/05/2023] Open
Affiliation(s)
- Sebastian Guelfi
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
| | - Juan A. Botia
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
- Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, Murcia, Spain
| | - Maria Thom
- Division of Neuropathology, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
| | | | - Marina Perona
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), National Scientific and Technical Research Council (CONICET), Argentina
| | - Lee Stanyer
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
| | - Lillian Martinian
- Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, Murcia, Spain
| | - Daniah Trabzuni
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
- Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - Colin Smith
- Academic Department of Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Robert Walker
- Academic Department of Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Mina Ryten
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
| | - Mark Reimers
- Neuroscience Program and Biomedical Engineering, Michigan State University, East Lansing, MI, USA
| | - Michael E. Weale
- Department Medical and Molecular Genetics, King’s College London, London, UK
| | - John Hardy
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
| | - Mar Matarin
- Department of Molecular Neuroscience, UCL, Institute of Neurology, Queen Square, London, UK
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London, WC1N 3, UK
| |
Collapse
|
9
|
Perona M, Thomasz L, Rossich L, Rodriguez C, Pisarev MA, Rosemblit C, Cremaschi GA, Dagrosa MA, Juvenal GJ. Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. Mol Cell Endocrinol 2018; 478:141-150. [PMID: 30125607 DOI: 10.1016/j.mce.2018.08.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 08/16/2018] [Accepted: 08/16/2018] [Indexed: 01/04/2023]
Abstract
Radiotherapy is one of the leading treatments for clinical cancer therapy. External beam radiotherapy has been proposed as an adjuvant treatment for patients bearing differentiated thyroid cancer refractory to conventional therapy. Our purpose was to study the combined effect of HDAC inhibitors (HDACi) and ionizing irradiation in thyroid cancer cell lines (Nthy-ori 3-1, WRO, TPC-1 and 8505c). HDACi radiosensitized thyroid cancer cells as evidenced by the reduction of survival fraction, whereas they had no effect in the normal cells. HDACi enhanced radiation-induced cell death in WRO cells. Gamma-H2AX foci number increased and persisted long after ionizing exposure in the HDACi-treated cells (WRO and TPC-1). Moreover, the expression of the repair-related gene Ku80 was differentially modulated only in the cancer cells, by the compounds at the protein and/or mRNA levels. We present in vitro evidence that HDACi can enhance the radiosensitivity of human thyroid cancer cells.
Collapse
Affiliation(s)
- Marina Perona
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina; National Scientific and Technical Research Council (CONICET), Av. Rivadavia 1917, 1033, Ciudad Autónoma de Buenos Aires, Argentina
| | - Lisa Thomasz
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina; National Scientific and Technical Research Council (CONICET), Av. Rivadavia 1917, 1033, Ciudad Autónoma de Buenos Aires, Argentina
| | - Luciano Rossich
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina
| | - Carla Rodriguez
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina
| | - Mario A Pisarev
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina
| | - Cinthia Rosemblit
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina; Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina
| | - Graciela A Cremaschi
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina; Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina
| | - María Alejandra Dagrosa
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina; National Scientific and Technical Research Council (CONICET), Av. Rivadavia 1917, 1033, Ciudad Autónoma de Buenos Aires, Argentina
| | - Guillermo J Juvenal
- Dept. of Radiobiology (CAC), National Atomic Energy Commission (CNEA), Av. Libertador 8250, 1429, San Martín, Buenos Aires, Argentina; National Scientific and Technical Research Council (CONICET), Av. Rivadavia 1917, 1033, Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
10
|
Thomasz L, Oglio R, Salvarredi L, Perona M, Rossich L, Copelli S, Pisarev M, Juvenal G. Regulation of NADPH oxidase NOX4 by delta iodolactone (IL-δ) in thyroid cancer cells. Mol Cell Endocrinol 2018; 470:115-126. [PMID: 28993239 DOI: 10.1016/j.mce.2017.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 10/04/2017] [Accepted: 10/04/2017] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Iodine is not used only by the thyroid to synthesize thyroid hormones but also directly influences a number of thyroid parameters such as thyroid proliferation and function. Several iodinated lipids, biosynthesized by the thyroid, were postulated as intermediaries in the action of iodide. Among these, iodolactone (IL-δ) and 2-iodohexadecanal (2-IHDA) have shown to inhibit several thyroid parameters. The antiproliferative effect of IL-δ is not restricted to the thyroid gland. IL-δ exhibits anti-tumor properties in breast cancer, neuroblastoma, glioblastoma, melanoma and lung carcinoma cells suggesting that IL-δ could be used as a chemotherapeutic agent. Moreover in a colon cancer cell line (HT-29), IL-δ induced cell death, and this effect was mediated by reactive oxygen species (ROS) generation. The aim of the present study was to analyze the sources of reactive oxygen species induced by IL-δ and to explore the contribution of ROS induced by IL-δ on cell proliferation and apoptosis. METHODOLOGY AND RESULTS Cancer thyroid follicular (WRO) and papilar (TPC-1) cells lines were treated with IL-δ. Proliferation and apoptosis was analyzed. IL-δ caused a significant loss of cell viability on WRO and TPC-1 cells in a concentration dependent manner and induced apoptosis after 3 h of treatment. Furthermore, IL-δ (10 μM) increased ROS production (39% WRO and 20% TPC-1). The concomitant treatment of WRO and TPC-1 cells with Trolox or NAC plus IL-δ abrogated the augment of ROS induced by IL-δ exposure. Additionally Trolox and NAC reversed the effect of IL-δ on cell proliferation and apoptosis. Only in WRO cells IL-δ upregulates NADPH oxidase NOX4 expression, and siRNA targeted knock-down of NOX4 attenuates ROS production, apoptosis (p < 0.05) and the inhibitory effect of IL-δ on cell proliferation and PCNA expression (p < 0.05). CONCLUSIONS The antiproliferative and pro-apoptotic effect of IL-δ is mediated by different mechanisms and pathway involving different sources of ROS generation depending on the cellular context.
Collapse
Affiliation(s)
- Lisa Thomasz
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina; CONICET, Argentina.
| | - Romina Oglio
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina
| | - Leonardo Salvarredi
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina
| | - Marina Perona
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina; CONICET, Argentina
| | - Luciano Rossich
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina
| | | | - Mario Pisarev
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina; CONICET, Argentina
| | - Guillermo Juvenal
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission, Buenos Aires 1429, Argentina; CONICET, Argentina.
| |
Collapse
|
11
|
Sidhu MK, Thompson PJ, Wandschneider B, Foulkes A, de Tisi J, Stretton J, Perona M, Thom M, Bonelli SB, Burdett J, Williams E, Duncan JS, Matarin M. The impact of brain-derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy. CNS Neurosci Ther 2018; 25:223-232. [PMID: 29952080 DOI: 10.1111/cns.13003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 06/04/2018] [Accepted: 06/05/2018] [Indexed: 01/08/2023] Open
Abstract
INTRODUCTION Medial temporal lobe epilepsy (mTLE) is the most common refractory focal epilepsy in adults. Around 30%-40% of patients have prominent memory impairment and experience significant postoperative memory and language decline after surgical treatment. BDNF Val66Met polymorphism has also been associated with cognition and variability in structural and functional hippocampal indices in healthy controls and some patient groups. AIMS We examined whether BDNF Val66Met variation was associated with cognitive impairment in mTLE. METHODS In this study, we investigated the association of Val66Met polymorphism with cognitive performance (n = 276), postoperative cognitive change (n = 126) and fMRI activation patterns during memory encoding and language paradigms in 2 groups of patients with mTLE (n = 37 and 34). RESULTS mTLE patients carrying the Met allele performed more poorly on memory tasks and showed reduced medial temporal lobe activation and reduced task-related deactivations within the default mode networks in both the fMRI memory and language tasks than Val/Val patients. CONCLUSIONS Although cognitive impairment in epilepsy is the result of a complex interaction of factors, our results suggest a role of genetic factors on cognitive impairment in mTLE.
Collapse
Affiliation(s)
- Meneka K Sidhu
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.,Epilepsy Society MRI Unit, Chesham Lane, Buckinghamshire, UK
| | - Pamela J Thompson
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.,Epilepsy Society MRI Unit, Chesham Lane, Buckinghamshire, UK
| | - Britta Wandschneider
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | - Alexandra Foulkes
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | - Jane de Tisi
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | - Jason Stretton
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.,Epilepsy Society MRI Unit, Chesham Lane, Buckinghamshire, UK
| | - Marina Perona
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.,Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| | - Maria Thom
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | | | - Jane Burdett
- Epilepsy Society MRI Unit, Chesham Lane, Buckinghamshire, UK
| | - Elaine Williams
- Epilepsy Society MRI Unit, Chesham Lane, Buckinghamshire, UK
| | - John S Duncan
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.,Epilepsy Society MRI Unit, Chesham Lane, Buckinghamshire, UK
| | - Mar Matarin
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.,Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| |
Collapse
|
12
|
Carpano M, Perona M, Rodriguez C, Nievas S, Olivera M, Santa Cruz GA, Brandizzi D, Cabrini R, Pisarev M, Juvenal GJ, Dagrosa MA. Experimental Studies of Boronophenylalanine ((10)BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment. Int J Radiat Oncol Biol Phys 2015; 93:344-52. [PMID: 26232853 DOI: 10.1016/j.ijrobp.2015.05.039] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 05/16/2015] [Accepted: 05/26/2015] [Indexed: 11/23/2022]
Abstract
PURPOSE Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina ((10)BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. METHODS AND MATERIALS The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 10(6) MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. RESULTS The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of (10)B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37 °C and 23 °C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R(2) = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R(2) = 0.81, logistic function fit). CONCLUSION We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual patient and lesion.
Collapse
Affiliation(s)
- Marina Carpano
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina
| | - Marina Perona
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina
| | - Carla Rodriguez
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina
| | - Susana Nievas
- Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín, Argentina
| | - Maria Olivera
- Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín, Argentina
| | - Gustavo A Santa Cruz
- Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín, Argentina
| | - Daniel Brandizzi
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina; School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina
| | - Romulo Cabrini
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina; School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina
| | - Mario Pisarev
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina; National Research Council of Argentina, Buenos Aires, Argentina; Department of Human Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
| | - Guillermo Juan Juvenal
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina; National Research Council of Argentina, Buenos Aires, Argentina
| | - Maria Alejandra Dagrosa
- Department of Radiobiology, National Atomic Energy Commission, San Martín, Argentina; National Research Council of Argentina, Buenos Aires, Argentina.
| |
Collapse
|
13
|
Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, Nahaboo Solim MA, Moens TG, Paublete RM, Ali SS, Perona M, Desai R, Smith KJ, Latcham J, Fulleylove M, Richardson JC, Hardy J, Edwards FA. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep 2015; 10:633-44. [PMID: 25620700 DOI: 10.1016/j.celrep.2014.12.041] [Citation(s) in RCA: 181] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Revised: 12/09/2014] [Accepted: 12/18/2014] [Indexed: 10/24/2022] Open
Abstract
We provide microarray data comparing genome-wide differential expression and pathology throughout life in four lines of "amyloid" transgenic mice (mutant human APP, PSEN1, or APP/PSEN1) and "TAU" transgenic mice (mutant human MAPT gene). Microarray data were validated by qPCR and by comparison to human studies, including genome-wide association study (GWAS) hits. Immune gene expression correlated tightly with plaques whereas synaptic genes correlated negatively with neurofibrillary tangles. Network analysis of immune gene modules revealed six hub genes in hippocampus of amyloid mice, four in common with cortex. The hippocampal network in TAU mice was similar except that Trem2 had hub status only in amyloid mice. The cortical network of TAU mice was entirely different with more hub genes and few in common with the other networks, suggesting reasons for specificity of cortical dysfunction in FTDP17. This Resource opens up many areas for investigation. All data are available and searchable at http://www.mouseac.org.
Collapse
Affiliation(s)
- Mar Matarin
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK; Reta Lila Research Laboratories and Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK
| | - Dervis A Salih
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Marina Yasvoina
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Damian M Cummings
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Sebastian Guelfi
- Reta Lila Research Laboratories and Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK
| | - Wenfei Liu
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Muzammil A Nahaboo Solim
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK; Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
| | - Thomas G Moens
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Rocio Moreno Paublete
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Shabinah S Ali
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK
| | - Marina Perona
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK
| | - Roshni Desai
- Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
| | - Kenneth J Smith
- Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
| | - Judy Latcham
- Department of Laboratory Animal Science, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK
| | - Michael Fulleylove
- Department of Laboratory Animal Science, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK
| | - Jill C Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK
| | - John Hardy
- Reta Lila Research Laboratories and Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK.
| | - Frances A Edwards
- Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.
| |
Collapse
|
14
|
Perona M, Dagrosa MA, Pagotto R, Casal M, Pignataro O, Pisarev MA, Juvenal GJ. Protective effect of an antithyroid compound against γ-radiation-induced damage in human colon cancer cells. Radiat Environ Biophys 2014; 53:611-619. [PMID: 24811726 DOI: 10.1007/s00411-014-0542-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Accepted: 04/13/2014] [Indexed: 06/03/2023]
Abstract
We have previously reported the radioprotective effect of propylthiouracil (PTU) on thyroid cells. The aim of the present study was to analyze whether tumor cells and normal cells demonstrate the same response to PTU. Human colon carcinoma cells were irradiated with γ-irradiation with or without PTU. We evaluated the clonogenic survival, intracellular reactive oxygen species levels, catalase, superoxide dismutase and glutathione peroxidase activities, and apoptosis by nuclear cell morphology and caspase-3 activity assays. Cyclic AMP (cAMP) levels were measured by radioimmunoassay. PTU treatment increased surviving cell fraction at 2 Gy (SF2) from 56.9 ± 3.6 in controls to 75.0 ± 3.5 (p < 0.05) and diminished radiation-induced apoptosis. In addition, we observed that the level of antioxidant enzymes' activity was increased in cells treated with PTU. Moreover, pretreatment with PTU increased intracellular levels of cAMP. Forskolin (p < 0.01) and dibutyryl cAMP (p < 0.05) mimicked the effect of PTU on SF2. Co-treatment with H89, an inhibitor of protein kinase A, abolished the radioprotective effect of PTU. PTU reduces the toxicity of ionizing radiation by increasing cAMP levels and also possibly through a reduction in apoptosis levels and in radiation-induced oxidative stress damage. We therefore conclude that PTU protects both normal and cancer cells during exposure to radiation in conditions mimicking the radiotherapy.
Collapse
Affiliation(s)
- Marina Perona
- Department of Radiobiology (CAC), National Atomic Energy Commission (CNEA), San Martín, Buenos Aires, Argentina
| | | | | | | | | | | | | |
Collapse
|
15
|
Perona M, Rodríguez C, Carpano M, Thomasz L, Nievas S, Olivera M, Thorp S, Curotto P, Pozzi E, Kahl S, Pisarev M, Juvenal G, Dagrosa A. Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma. Radiat Environ Biophys 2013; 52:363-373. [PMID: 23636505 DOI: 10.1007/s00411-013-0470-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Accepted: 04/10/2013] [Indexed: 06/02/2023]
Abstract
We have shown that boron neutron capture therapy (BNCT) could be an alternative for the treatment of poorly differentiated thyroid carcinoma (PDTC). Histone deacetylase inhibitors (HDACI) like sodium butyrate (NaB) cause hyperacetylation of histone proteins and show capacity to increase the gamma irradiation effect. The purpose of these studies was to investigate the use of the NaB as a radiosensitizer of the BNCT for PDTC. Follicular thyroid carcinoma cells (WRO) and rat thyroid epithelial cells (FRTL-5) were incubated with 1 mM NaB and then treated with boronophenylalanine ¹⁰BPA (10 μg ¹⁰B ml⁻¹) + neutrons, or with 2, 4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ¹⁰BOPP (10 μg ¹⁰B ml⁻¹) + neutrons, or with a neutron beam alone. The cells were irradiated in the thermal column facility of the RA-3 reactor (flux = (1.0 ± 0.1) × 10¹⁰ n cm⁻² s⁻¹). Cell survival decreased as a function of the physical absorbed dose in both cell lines. Moreover, the addition of NaB decreased cell survival (p < 0.05) in WRO cells incubated with both boron compounds. NaB increased the percentage of necrotic and apoptotic cells in both BNCT groups (p < 0.05). An accumulation of cells in G2/M phase at 24 h was observed for all the irradiated groups and the addition of NaB increased this percentage. Biodistribution studies of BPA (350 mg kg⁻¹ body weight) 24 h after NaB injection were performed. The in vivo studies showed that NaB treatment increases the amount of boron in the tumor at 2-h post-BPA injection (p < 0.01). We conclude that NaB could be used as a radiosensitizer for the treatment of thyroid carcinoma by BNCT.
Collapse
Affiliation(s)
- M Perona
- Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, San Martín 1650, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Thomasz L, Oglio R, Rossich L, Villamar S, Perona M, Salvarredi L, Dagrosa A, Pisarev MA, Juvenal GJ. 6 Iodo-δ-lactone: a derivative of arachidonic acid with antitumor effects in HT-29 colon cancer cells. Prostaglandins Leukot Essent Fatty Acids 2013; 88:273-80. [PMID: 23375358 DOI: 10.1016/j.plefa.2013.01.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Revised: 12/26/2012] [Accepted: 01/04/2013] [Indexed: 01/21/2023]
Abstract
BACKGROUND IL-δ (5-hydroxy-6 iodo-8,11,14-eicosatrienoic delta lactone) an iodinated arachidonic acid (AA) derivative, is one of the iodolipids biosynthesized by the thyroid. Although IL-δ regulates several thyroid parameters such as cell proliferation and goiter growth it was found that this iodolipid inhibits the growth of other non thyroid cell lines. OBJECTIVES To study the effect of IL-δ on cell proliferation and apoptosis in the colon cancer cell line HT-29. RESULTS Treatment with IL-δ reduced cell viability in a concentration-dependent manner: 1μM 20%, 5μM 25%, 10μM 31%, 50μM 47% and caused a significant decrease of PCNA expression (25%). IL-δ had pro-apoptotic effects, evidenced by morphological features of programmed cell death such as pyknosis, karyorrhexis, cell shrinkage and cell blebbing observed by fluorescence microscopy, and an increase in caspase-3 activity and in Bax/Bcl-2 ratio (2.5 after 3h of treatment). Furthermore, IL-δ increased ROS production (30%) and lipid peroxidation levels (19%), suggesting that apoptosis could be a result of increased oxidative stress. A maximum increase in c-fos and c-jun protein expression in response to IL-δ was observed 1h after initiation of the treatment. IL-δ also induced a tumour growth delay of 70% compared to the control group in NIH nude mice implanted with HT-29 cells. CONCLUSION Our study shows that IL-δ inhibits cell growth and induces apoptosis in the colon cancer cell line, HT-29 and opens the possibility that IL-δ could be a potential useful chemotherapy agent.
Collapse
Affiliation(s)
- Lisa Thomasz
- Nuclear Biochemistry Division, Argentine National Atomic Energy Commission Buenos Aires 1429, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Perona M, Dagrosa MA, Pagotto R, Casal M, Pignataro OP, Pisarev MA, Juvenal GJ. Protection against radiation-induced damage of 6-propyl-2-thiouracil (PTU) in thyroid cells. Radiat Res 2013; 179:352-60. [PMID: 23398355 DOI: 10.1667/rr2658.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Many epidemiologic studies have shown that the exposure to high external radiation doses increases thyroid neoplastic frequency, especially when given during childhood or adolescence. The use of radioprotective drugs may decrease the damage caused by radiation therapy and therefore could be useful to prevent the development of thyroid tumors. The aim of this study was to investigate the possible application of 6-propyl-2-thiouracil (PTU) as a radioprotector in the thyroid gland. Rat thyroid epithelial cells (FRTL-5) were exposed to different doses of γ irradiation with or without the addition of PTU, methimazole (MMI), reduced glutathione (GSH) and perchlorate (KClO4). Radiation response was analyzed by clonogenic survival assay. Cyclic AMP (cAMP) levels were measured by radioimmunoassay (RIA). Apoptosis was quantified by nuclear cell morphology and caspase 3 activity assays. Intracellular reactive oxygen species (ROS) levels were measured using the fluorescent dye 2',7'-dichlorofluorescein-diacetate. Catalase, superoxide dismutase and glutathione peroxidase activities were also determined. Pretreatment with PTU, MMI and GSH prior to irradiation significantly increased the surviving cell fraction (SF) at 2 Gy (P < 0.05), while no effect was observed with KClO4. An increase in extracellular levels of cAMP was found only in PTU treated cells in a dose and time-dependent manner. Cells incubated with agents that stimulate cAMP (forskolin and dibutyril cAMP) mimicked the effect of PTU on SF. Moreover, pretreatment with the inhibitor of protein kinase A, H-89, abolished the radioprotective effect of PTU. PTU treatment diminished radiation-induced apoptosis and protected cells against radiation-induced ROS elevation and suppression of the antioxidant enzyme's activity. PTU was found to radioprotect normal thyroid cells through cAMP elevation and reduction in both apoptosis and radiation-induced oxidative stress damage.
Collapse
Affiliation(s)
- Marina Perona
- Department of Radiobiology, National Atomic Energy Commission, University of Buenos Aires, Department of Human Biochemistry, School of Medicine, Argentina
| | | | | | | | | | | | | |
Collapse
|
18
|
|
19
|
Perona M, Pontiggia O, Carpano M, Thomasz L, Thorp S, Pozzi E, Simian M, Kahl S, Juvenal G, Pisarev M, Dagrosa A. In vitro studies of cellular response to DNA damage induced by boron neutron capture therapy. Appl Radiat Isot 2011; 69:1732-6. [DOI: 10.1016/j.apradiso.2011.03.044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Revised: 03/21/2011] [Accepted: 03/31/2011] [Indexed: 11/26/2022]
|
20
|
Dagrosa A, Carpano M, Perona M, Thomasz L, Nievas S, Cabrini R, Juvenal G, Pisarev M. Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer. Appl Radiat Isot 2011; 69:1752-5. [PMID: 21570311 DOI: 10.1016/j.apradiso.2011.02.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Revised: 02/15/2011] [Accepted: 02/17/2011] [Indexed: 10/18/2022]
Abstract
The aim of these studies was to evaluate the possibility of treating differentiated thyroid cancer by BNCT. These carcinomas are well controlled with surgery followed by therapy with (131)I; however, some patients do not respond to this treatment. BPA uptake was analyzed both in vitro and in nude mice implanted with cell lines of differentiated thyroid carcinoma. The boron intracellular concentration in the different cell lines and the biodistribution studies showed the selectivity of the BPA uptake by this kind of tumor.
Collapse
Affiliation(s)
- A Dagrosa
- Department of Radiobiology, National Atomic Energy Commission (CNEA), San Martin, Argentina.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Dagrosa MA, Crivello M, Perona M, Thorp S, Santa Cruz GA, Pozzi E, Casal M, Thomasz L, Cabrini R, Kahl S, Juvenal GJ, Pisarev MA. First evaluation of the biologic effectiveness factors of boron neutron capture therapy (BNCT) in a human colon carcinoma cell line. Int J Radiat Oncol Biol Phys 2011; 79:262-8. [PMID: 20932650 DOI: 10.1016/j.ijrobp.2010.07.020] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Revised: 06/27/2010] [Accepted: 07/07/2010] [Indexed: 11/16/2022]
Abstract
PURPOSE DNA lesions produced by boron neutron capture therapy (BNCT) and those produced by gamma radiation in a colon carcinoma cell line were analyzed. We have also derived the relative biologic effectiveness factor (RBE) of the neutron beam of the RA-3- Argentine nuclear reactor, and the compound biologic effectiveness (CBE) values for p-boronophenylalanine ((10)BPA) and for 2,4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ((10)BOPP). METHODS AND MATERIALS Exponentially growing human colon carcinoma cells (ARO81-1) were distributed into the following groups: (1) BPA (10 ppm (10)B) + neutrons, (2) BOPP (10 ppm (10)B) + neutrons, (3) neutrons alone, and (4) gamma rays ((60)Co source at 1 Gy/min dose-rate). Different irradiation times were used to obtain total absorbed doses between 0.3 and 5 Gy (±10%) (thermal neutrons flux = 7.5 10(9) n/cm(2) sec). RESULTS The frequency of micronucleated binucleated cells and the number of micronuclei per micronucleated binucleated cells showed a dose-dependent increase until approximately 2 Gy. The response to gamma rays was significantly lower than the response to the other treatments (p < 0.05). The irradiations with neutrons alone and neutrons + BOPP showed curves that did not differ significantly from, and showed less DNA damage than, irradiation with neutrons + BPA. A decrease in the surviving fraction measured by 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromide (MTT) assay as a function of the absorbed dose was observed for all the treatments. The RBE and CBE factors calculated from cytokinesis block micronucleus (CBMN) and MTT assays were, respectively, the following: beam RBE: 4.4 ± 1.1 and 2.4 ± 0.6; CBE for BOPP: 8.0 ± 2.2 and 2.0 ± 1; CBE for BPA: 19.6 ± 3.7 and 3.5 ± 1.3. CONCLUSIONS BNCT and gamma irradiations showed different genotoxic patterns. To our knowledge, these values represent the first experimental ones obtained for the RA-3 in a biologic model and could be useful for future experimental studies for the application of BNCT to colon carcinoma.
Collapse
|
22
|
Schmitt AG, Hall FS, Perona M, Ortega G, Hofmann M, Sora I, Uhl GR, Riederer P, Lesch KP, Gerlach M, Grünblatt E. Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Dagrosa MA, Thomasz L, Longhino J, Perona M, Calzetta O, Blaumann H, Rebagliati RJ, Cabrini R, Kahl S, Juvenal GJ, Pisarev MA. Optimization of boron neutron capture therapy for the treatment of undifferentiated thyroid cancer. Int J Radiat Oncol Biol Phys 2007; 69:1059-66. [PMID: 17967301 DOI: 10.1016/j.ijrobp.2007.04.061] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2006] [Revised: 04/18/2007] [Accepted: 04/19/2007] [Indexed: 10/22/2022]
Abstract
PURPOSE To analyze the possible increase in efficacy of boron neutron capture therapy (BNCT) for undifferentiated thyroid carcinoma (UTC) by using p-boronophenylalanine (BPA) plus 2,4-bis (alpha,beta-dihydroxyethyl)-deutero-porphyrin IX (BOPP) and BPA plus nicotinamide (NA) as a radiosensitizer of the BNCT reaction. METHODS AND MATERIALS Nude mice were transplanted with a human UTC cell line (ARO), and after 15 days they were treated as follows: (1) control, (2) NCT (neutrons alone), (3) NCT plus NA (100 mg/kg body weight [bw]/day for 3 days), (4) BPA (350 mg/kg bw) + neutrons, (5) BPA + NA + neutrons, and (6) BPA + BOPP (60 mg/kg bw) + neutrons. The flux of the mixed (thermal + epithermal) neutron beam was 2.8 x 10(8) n/cm(2)/sec for 83.4 min. RESULTS Neutrons alone or with NA caused some tumor growth delay, whereas in the BPA, BPA + NA, and BPA + BOPP groups a 100% halt of tumor growth was observed in all mice at 26 days after irradiation. When the initial tumor volume was 50 mm(3) or less, complete remission was found with BPA + NA (2 of 2 mice), BPA (1 of 4), and BPA + BOPP (7 of 7). After 90 days of complete regression, recurrence of the tumor was observed in BPA + NA (2 of 2) and BPA + BOPP (1 of 7). The determination of apoptosis in tumor samples by measurements of caspase-3 activity showed an increase in the BNCT (BPA + NA) group at 24 h (p < 0.05 vs. controls) and after the first week after irradiation in the three BNCT groups. Terminal transferase dUTP nick end labeling analysis confirmed these results. CONCLUSIONS Although NA combined with BPA showed an increase of apoptosis at early times, only the group irradiated after the combined administration of BPA and BOPP showed a significantly improved therapeutic response.
Collapse
Affiliation(s)
- Maria Alejandra Dagrosa
- Department of Radiobiology (Constituyentes Atomic Center), National Atomic Energy Commission of Argentina, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Molla M, Balboa A, Espinos J, Perello A, Perona M, Salas A, Toscas J, Escude L, Linero D, Miralbell R. 2305. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Fracchia M, Galatola G, Sarotto I, Guraldo V, Perona M, Pera A, Risio M. Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas. Dig Liver Dis 2005; 37:509-14. [PMID: 15975538 DOI: 10.1016/j.dld.2005.01.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2004] [Accepted: 01/14/2005] [Indexed: 12/11/2022]
Abstract
BACKGROUND Deoxycholic acid induced programmed cell death and an imbalance with cell proliferation may favour colorectal tumourigenesis according to 'in vitro' studies, but information is lacking on the relationships occurring 'in vivo' in humans. AIMS To evaluate whether serum deoxycholic acid is associated with programmed cell death and cell proliferation in colonic mucosa. METHODS In 10 patients with colorectal adenomas, we measured fasting serum levels of bile acids; and, in normal colonic mucosa, programmed cell death by the TUNEL technique and cell proliferation by immunohistochemical staining with anti-Ki67. Total and compartmental indices for both activities were calculated. RESULTS Among serum bile acids, only total deoxycholic acid (median: 0.89 micromol/L +/- 0.54 95% CI), showed a significant positive correlation with the total and basal compartments PCD Index (r = 0.68, p < 0.05). Total proliferation index showed no correlation with either total PCD Index, or bile acids. Within the median compartment of the crypt, cell proliferation was negatively associated with all unconjugated bile acids. CONCLUSIONS The positive association between deoxycholic acid and programmed cell death in the basal compartment of the crypt, and the negative association of cell proliferation and unconjugated bile acids in the median compartment, do not seem to support the co-carcinogenic effect of deoxycholic acid.
Collapse
Affiliation(s)
- M Fracchia
- Gastroenterology Unit, Institute for Cancer Research and Treatment--IRCC, Strada Provinciale N degree 142, Candiolo, Italy
| | | | | | | | | | | | | |
Collapse
|
26
|
Mearin F, Perelló A, Perona M. Calidad de vida en los pacientes con síndrome del intestino irritable. Gastroenterol Hepatol 2004. [DOI: 10.1157/13058927] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
27
|
Campogrande M, Viora E, Errante G, Bastonero S, Sciarrone A, Grassi Pirrone P, Perona M, Mancini G, Dall'Amico D, Pavanello E, Guaraldo V. Correlations between first and second trimester markers for Down's syndrome screening. J Med Screen 2002; 8:163-4. [PMID: 11678558 DOI: 10.1136/jms.8.3.163] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- M Campogrande
- Centro di Ecografia e Diagnosi Prenatale, Ospedale Sant'Anna, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
de Dios A, Perona M, García Martínez A, Estruch R. [Peritoneal tuberculosis and the concentration of CA-125 antigen in plasma]. Med Clin (Barc) 1999; 113:679. [PMID: 10618790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
29
|
Perona M, Mancini G, Dall'Amico D, Guaraldo V, Carbonara A. Influence of smoking habits on Down's syndrome risk evaluation at mid-trimester through biochemical screening. Int J Clin Lab Res 1998; 28:179-82. [PMID: 9801929 DOI: 10.1007/s005990050040] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Expectant mothers who smoke have higher levels of maternal serum alpha-fetoprotein and lower levels of unconjugated estriol and total human chorionic gonadotrophin than non-smoking mothers. This significantly affects performance of screening for Down's syndrome. This study includes 22,169 pregnant women: 18,876 non-smokers, 2,660 smoking < or = 10 cigarettes/day, and 633 smoking > 10 cigarettes/day. Mean maternal age (32.6 years), maternal weight (60.5 kg), and gestational age (114.7 days) were similar or only slightly different between the three groups. To verify the effects of smoking on screening, we studied retrospectively 130 sequential Down's syndrome cases (47 from the screening program, 83 from the prenatal diagnosis program). The proportion of smokers in the Down's syndrome and unaffected pregnancies was similar, whilst the false-positive rate and detection rate, based on fetal outcome, differed: false-positive rates were 5.63% in smokers and 9.42% in non-smokers, and detection rate 55.6% in smokers and 83.0% in non-smokers. Since the prevalence of Down's syndrome pregnancies was the same at mid-trimester in smokers and non-smokers and the proportion of smokers was not related to maternal age, we propose an adjustment of the Down's syndrome risk evaluation algorithm according to smoking habits.
Collapse
Affiliation(s)
- M Perona
- Laboratorio Analisi Ospedale S. Anna, C.so Spezia, Turin, Italy
| | | | | | | | | |
Collapse
|
30
|
Perona M, Mancini G, Dall'Amico D, Guaraldo V, Carbonara A. Repeat testing of mothers with high human chorionic gonadotrophin levels in Down's syndrome screening. Int J Clin Lab Res 1998; 27:253-6. [PMID: 9506270 DOI: 10.1007/bf02912467] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Multiples of medians of serum markers are assumed to be independent of gestational age: every algorithm used for Down's syndrome risk evaluation is based on this hypothesis. However, our former observations suggested that multiples of medians of human chorionic gonadotrophin in Down's syndrome are dependent on gestatational age. Furthermore, observations on 84 Down's syndrome cases confirmed that human chorionic gonadotrophin multiples of medians in samples drawn at 15-17 weeks are approximately 10% lower than in samples drawn at 18-21 weeks, thus showing that the human chorionic gonadotrophin concentration decreases about 10% less than expected. The control group comprised 554 women with two blood samples and normal human chorionic gonadotrophin at first sampling. A further group of 532 women with multiples of medians at first sampling > 1.8 was examined with the aim of excluding an association between the human chorionic gonadotrophin trend in Down's syndrome and high starting values. The trend is peculiar to human chorionic gonadotrophin in Down's syndrome pregnancies and may help to explain the increase in detection rate with gestational age. Based on these findings, screening can be optimized, thus improving performance.
Collapse
Affiliation(s)
- M Perona
- Azienda Ospedaliera OIRM-S. Anna, Turin, Italy
| | | | | | | | | |
Collapse
|
31
|
Giai M, Roagna R, Ponzone R, Biglia N, Sgro L, Perona M, Sismondi P. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res 1996; 16:875-81. [PMID: 8687144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Tissue Polypeptide-specific Antigen (TPS) and CA 15.3 are two of the most widely studied tumor markers in the serum of breast cancer patients. TPS is a tumor associated proliferative marker which belongs to the cytoskeleton. CA 15.3 is a high molecular weight glycoprotein of clinical relevance in the monitoring of treatment and the detection of recurrence in breast cancer patients. PATIENTS AND METHODS Serum values of TPS and CA 15.3 were measured in a prospective series of patients with primary breast cancer (n=267) and benign breast disease (n=46). The cut-off levels (95% specificity) determined for each test were 80 U/I for TPS and 30 k/U/l for CA 15.3. RESULTS The diagnostic sensitivity was 0.31 for TPS and 0.32 for CA 15.3 for the detection of breast cancer. Serum TPS levels in breast cancer patients showed a relatively low positivity rate (33%), which was comparable with that of CA 15.3. Higher concentrations of TPS were found in cases with locally more advanced disease as well as in G3 tumors. By contrast, CA 15.3 basal levels were solely related to tumor size and nodal involvement. TPS and CA 15.3 levels were not related to estrogen and progesterone receptor status, peritumoral vessel invasion, multifocality and the in situ component of the tumor. After primary treatment, 20 patients developed distant metastases. In metastatic breast cancer patients TPS was more frequently and more markedly elevated than CA 15.3. In progressive disease, elevated values of TPS and CA 15.3 were found in 85% and 50%, respectively. The mean lead time was 10 months for TPS and 14 months for CA 15.3. Increasing values of TPS were independent of the site of metastasis, whereas elevated levels of CA 15.3 were mainly related to visceral metastasis. Local recurrences were usually associated with low levels of TPS and CA 15.3. By contrast, elevated values of TPS in locally recurred cases indicated rapidly progressive disease. CONCLUSIONS Our study indicates that TPS and CA 15.3 are not helpful in distinguishing patients with breast cancer from patients with benign breast lesions. Nevertheless, at the time of diagnosis increased serum levels of the markers may facilitate the selection of high risk patients for whom additional treatment and careful follow up studies should be undertaken. Furthermore, TPS seems to be a reliable tumor marker for the early diagnosis of metastatic breast carcinoma independent of the site of metastasis, while increasing values of CA 15.3 are mainly related to visceral involvement.
Collapse
Affiliation(s)
- M Giai
- Institute of Gynecology and Obstetrics, Department of Gynecological Oncology, University of Turin, Italy
| | | | | | | | | | | | | |
Collapse
|
32
|
Mancini G, Perona M, Dall'Amico D, Bollati C, Albano F, Mazzone R, Rosso M, Grosso E, Migone N, Fiocchi F. Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study. Int J Clin Lab Res 1994; 24:49-53. [PMID: 7514056 DOI: 10.1007/bf02592410] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The risk of Down's syndrome pregnancies can be estimated by quantitation of maternal serum markers, namely alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin (triple test). A prospective study of 2892 pregnant women (median age 33.5 years) is reported. The detection rate of Down's syndrome pregnancies was 80% (confidence intervals 45%-100%) when a risk of 1:380 or greater was considered "screen positive", the false positive rate was 13.3% (confidence intervals 12.0%-14.5%). The importance of the accurate assessment of gestational age and the time of blood sampling are emphasized. Our findings are compared with similar studies performed in other laboratories.
Collapse
Affiliation(s)
- G Mancini
- Ente Ospedaliero Sant'Anna, USL-IX, Turin, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Anabolic steroids extracted from bovine serum by means of organic solvents or solid-phase extraction techniques with C18 cartridges are not suitable for quantitative analysis by gas chromatography-mass spectrometry (GC-MS); therefore, they were extracted from serum by Extrelut columns (Merck; Germany), eluted with diethyl ether, and purified by a solid-phase extraction technique using amino (NH2) columns. The resulting clean extract was treated with heptafluorobutyric anhydride (HFBA); this formed a derivative suitable for GC-MS analysis. Using selected ion monitoring (SIM), quantities as small as 40 pg/mL can be detected.
Collapse
Affiliation(s)
- M Perona
- Analysis Laboratory, Sant'Anna Hospital, Turin, Italy
| | | |
Collapse
|
34
|
Mancini G, Perona M, Dall'Amico CD, Bollati C, Fulvia A, Carbonara AO. hCG, AFP, and uE3 patterns in the 14-20th weeks of Down's syndrome pregnancies. Prenat Diagn 1992; 12:619-24. [PMID: 1380711 DOI: 10.1002/pd.1970120709] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- G Mancini
- Ente Ospedaliero Sant'Anna, USL IX, Torino, Italy
| | | | | | | | | | | |
Collapse
|
35
|
Mancini G, Perona M, Dall'Amico D, Bollati C, Albano F, Mazzone R, Rosso M, Carbonara AO. Screening for fetal Down's syndrome with maternal serum markers--an experience in Italy. Prenat Diagn 1991; 11:245-52. [PMID: 1716761 DOI: 10.1002/pd.1970110406] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effectiveness of maternal serum alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin in screening for Down's syndrome (DS) was evaluated on 840 women who underwent amniocentesis for fetal karyotype on account of their age. The risk of a DS pregnancy was established using the method of Wald et al. (1988b), which combines the age-specific risk with that indicated by the levels of the three serum markers. In women over 35, at cut-off risk levels of 1:250 and 1:380, the false-positive rate was 24 and 34 per cent, respectively. In all nine cases of DS, the estimated risk was higher than 1:250. The best screening strategy with the lowest false-positive rate was obtained by combining the three serum markers. The results suggest that this kind of screening can be proposed during genetic counselling for women under 35 and older women wishing to avoid the risk of miscarriage induced by amniocentesis.
Collapse
Affiliation(s)
- G Mancini
- Ente Ospedaliero Sant'Anna, USL IX, Torino, Italy
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Sagredo E, Pino A, Ibáñez P, Martos F, Perona M. [Benign fibrohistiocytoma of the soft palate]. Av Odontoestomatol 1989; 5:16-20. [PMID: 2561341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A case of benign fibrohistiocytoma of the soft palate in a 61 years-old woman is presented and current approaches to histogenesis of fibro-histiocytic tumors commented.
Collapse
|
37
|
Ibañez P, Sagrado E, Pino A, Martos F, Perona M, Ramos P. [Odontogenic myxoma of the mandible]. Rev Actual Estomatol Esp 1988; 48:59-60, 63-5. [PMID: 3272023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
38
|
de Sanctis C, Aimar A, Corrias A, Gugliotta R, Perona M. [Diagnosis of congenital adrenogenital syndromes]. MINERVA ENDOCRINOL 1987; 12:107-15. [PMID: 3302649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
39
|
Perona M, Ibáñez P, Sagredo E, Pino A, Ortiz G. [Langerhans cells in normal, inflamed and hydantoin hyperplastic gingiva]. Av Odontoestomatol 1987; 3:57-60, 63-5. [PMID: 3507206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
40
|
Perona M, Ibáñez P, Sagredo E, Pino A, Ortiz G. [Granular cell tumor of the gingiva. Report of a case and review of the terminological, clinical, histogenic and pathological criteria]. Av Odontoestomatol 1986; 2:211-3, 215-6, 219-20. [PMID: 3030352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
41
|
Perona M, Pino A, Ibañez P, Sagredo E, Ramos P, Ortiz G. [Gingival melanosis in a case of hyperthyroidism]. Av Odontoestomatol 1986; 2:123-5. [PMID: 3464287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
42
|
Perona M, Ibáñez P, Pino A, Sagredo E, Ortiz G. [Transport of immunoglobulins in the gingival epithelium. III. In chronic nonspecific inflammation]. Av Odontoestomatol 1986; 2:77-81. [PMID: 3533094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
43
|
Perona M, Sabredo E, Pino A, Ibañez P, Ortiz G. [Immunoglobulin transport in the gingival epithelium. II. Clinically normal gingiva]. Av Odontoestomatol 1986; 2:7-14. [PMID: 3460599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
44
|
Pino A, Perona M, Ibañez P, Sagredo E, Tabernero M, Ramos P, Urcelay B, Ortiz G. [Epithelial components in gingival hyperplasia due to hydantoin and their possible pathogenic significance]. Rev Actual Estomatol Esp 1985; 45:37-40, 43. [PMID: 3869985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
45
|
Voglino GF, Aimone V, Perona M. [Synthesis of beta-casein in hormone-dependent breast tumors]. Minerva Ginecol 1980; 32:373-8. [PMID: 7393482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
46
|
Benso L, Campagnoli C, Fessia L, Galante AM, Perona M. [Gas chromatographic profile of urinary steroids in the diagnosis of infantile adrenogenital syndromes]. Minerva Pediatr 1976; 28:1659-74. [PMID: 1012201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
47
|
Benso L, Campagnoli C, Giacchino M, Perona M. [Evaluations of hydroxylation indices in the diagnosis of adrenogenital syndrome]. Minerva Pediatr 1976; 28:538-9. [PMID: 979944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
48
|
Campagnoli C, Fessia L, Peris C, Perona M, Rosso M. [Hyperandrogenic adrenal gland diseases of gynecological interest. I. Biosynthesis and catabolism of adrenal cortex hormones]. Minerva Ginecol 1976; 28:1-13. [PMID: 1256704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
49
|
Fumero S, Mondino A, Zanolo G, Aimone V, Campagnoli C, Perona M. 32. The determination of the oestradiol receptor in normal and in neoplastic human mammary tissue. ACTA ACUST UNITED AC 1975. [DOI: 10.1016/0022-4731(75)90254-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Aimone V, Campagnoli C, Fumero S, Perona M, Zanolo G. [The determination of receptors for estradiol in breast carcinomas and the possibilities of endocrine therapy]. Minerva Ginecol 1975; 27:493-504. [PMID: 174031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|